Phil Y. C. Chen, D.O., a Professional Corporation

Phil Y. C. Chen, D.O., a Professional Corporation was paid $273K by Medicaid between Jan 2018 and Oct 2024, across 5 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 93% of everything it billed.

33Billing provider infoPHIL Y. C. CHEN, D.O., A PROFESSIONAL CORPORATION
HENDERSON, NV 89074

33aNPI1679827679assigned 10/30/2012

33bProvider typePrimary Care Clinic/Center

28Total paid$273K

24GClaims3,630

24DCodes billed5

24AFirst – last monthJan 2018 – Oct 2024

Compared with peers

Next to other Primary Care Clinic/Center providers in Nevada

Rank by total paid#15 of 42

Median peer was paid$57K

This provider vs. median4.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	380	$30K
2019	922	$68K
2020	62	$6K
2021	93	$9K
2022	945	$68K
2023	736	$57K
2024incomplete	492	$34K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	93%	3,097	2,707	$254K
99215	Doctor's office visit, returning patient (complex)Prolong outpt/office vis	4.9%	121	119	$13K
98926		<1%	79	69	$3K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	19	19	$2K
80305		<1%	314	308	$388.78

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCHEN, PHIL (PRESIDENT)